| Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. | |
| | |
MedLine Citation:
|
PMID: 16162703 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
STUDY OBJECTIVES: We have previously shown that tiotropium at 18 mug reduces lung hyperinflation and dyspnea during exercise and improves exercise tolerance in patients with COPD. The present study was designed to gain further insight into the duration of improvements. DESIGN, PATIENTS, AND INTERVENTIONS: A randomized, double-blind, placebo-controlled, parallel-group study was conducted in 261 COPD patients (mean age, 62.5 +/- 7.4 years [+/- SD]; 189 men and 72 women; mean FEV1, 1.2 +/- 0.4 L [43 +/- 12.7% predicted]). On day 0 (first dose), day 21, and day 42 of treatment, pulmonary function tests were performed before and 1 h 20 min after dosing, followed by a constant work rate cycle ergometry test (75% maximum work capacity) to symptom limitation at 2.25 h after dosing. On day 42, an additional constant work rate cycle ergometry test was performed at 8 h after dosing. RESULTS: Adjusted mean (+/- SE) endurance time (ET) on day 42 was 803 +/- 40 s (tiotropium), vs 568 +/- 42 s (placebo) at 2.25 h after dosing (primary end point; treatment difference, 236 +/- 58 s; p = 0.0001) and 665 +/- 40 s (tiotropium) vs 494 +/- 42 s (placebo) at 8 h after dosing (treatment difference, 171 +/- 58 s; p = 0.0035). Adjusted mean dyspnea intensity at isotime on day 42 was 4.60 +/- 0.16 Borg units (tiotropium), vs 5.65 +/- 0.16 Borg units (placebo) at 2.25 h after dosing (p < 0.001), and 5.54 +/- 0.17 Borg units (tiotropium) vs 6.51 +/- 0.18 Borg units (placebo) at 8 h after dosing (p < 0.001). Adjusted mean pre-exercise inspiratory capacity (IC) on day 42 was 2.41 +/- 0.03 L (tiotropium) vs 2.19 +/- 0.03 L (placebo) at 2.25 h after dosing (p < 0.001), and 2.31 +/- 0.03 L (tiotropium) vs 2.16 +/- 0.03 L (placebo) at 8 h after dosing (p < 0.001). The significant increase in IC with tiotropium compared with placebo was maintained throughout exercise. CONCLUSIONS: The present study confirms that tiotropium reduces lung hyperinflation at rest and during exercise, reduces exertional dyspnea, and improves symptom-limited exercise tolerance in COPD patients. Furthermore, this study shows that this improvement is present at 2.25 h and at 8 h after dosing after 6 weeks of treatment. |
| | |
Authors:
|
François Maltais; Alan Hamilton; Darcy Marciniuk; Paul Hernandez; Frank C Sciurba; Kai Richter; Steven Kesten; Denis O'Donnell |
Related Documents
:
|
1889243 - Maximum intensity exercise training in patients with chronic obstructive pulmonary dise... 12832683 - Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation d... 19876883 - Bed exercises following total hip replacement: 1 year follow-up of a single-blinded ran... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Chest Volume: 128 ISSN: 0012-3692 ISO Abbreviation: Chest Publication Date: 2005 Sep |
Date Detail:
|
Created Date: 2005-09-15 Completed Date: 2005-11-08 Revised Date: 2012-09-10 |
Medline Journal Info:
|
Nlm Unique ID: 0231335 Medline TA: Chest Country: United States |
Other Details:
|
Languages: eng Pagination: 1168-78 Citation Subset: AIM; IM |
Affiliation:
|
Centre de Recherche, Hôpital Laval, Institut Universitaire de Cardiologie et de Pneumologie de l'Université Laval, 725 Chemin Ste-Foy, Québec, QC, G1V 4G5, Canada. francois.maltais@med.ulaval.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Bronchodilator Agents / pharmacology*, therapeutic use Double-Blind Method Exercise Test Exercise Tolerance / drug effects* Female Humans Male Pulmonary Disease, Chronic Obstructive / drug therapy* Respiratory Function Tests Scopolamine Derivatives / pharmacology*, therapeutic use Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Bronchodilator Agents; 0/Scopolamine Derivatives; 136310-93-5/tiotropium |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Results of a culturally directed asthma intervention program in an inner-city Latino community.
Next Document: Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and ...